Acasunlimab clinical trials
Also written GEN1046.
How each study uses acasunlimab has had a first review. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2021 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test acasunlimab, phase 3 first.
Studies
Open first, then newest update. How each study uses acasunlimab has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)Active, not recruitingPhase 3GenmabNCT06635824Written as AcasunlimabReport a problem
- Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)TerminatedPhase 2GenmabNCT06984328Written as AcasunlimabReport a problem
- Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung CancerTerminatedPhase 2GenmabNCT05117242Written as AcasunlimabReport a problem
- GEN1046 Safety Trial in Patients With Malignant Solid TumorsTerminatedPhase 1/2GenmabNCT03917381Written as AcasunlimabReport a problem
- GEN1046 Safety and PK in Subjects With Advanced Solid MalignanciesCompletedPhase 1GenmabNCT04937153Written as AcasunlimabReport a problem
- GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial CancerWithdrawnPhase 2GenmabNCT06046274Written as AcasunlimabReport a problem
Tested with established drugs · 6 — they are given beside it
- Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)Active, not recruitingPhase 3GenmabNCT06635824Written as AcasunlimabReport a problem
- Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)TerminatedPhase 2GenmabNCT06984328Written as AcasunlimabReport a problem
- Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung CancerTerminatedPhase 2GenmabNCT05117242Written as AcasunlimabReport a problem
- GEN1046 Safety Trial in Patients With Malignant Solid TumorsTerminatedPhase 1/2GenmabNCT03917381Written as AcasunlimabReport a problem
- GEN1046 Safety and PK in Subjects With Advanced Solid MalignanciesCompletedPhase 1GenmabNCT04937153Written as AcasunlimabReport a problem
- GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial CancerWithdrawnPhase 2GenmabNCT06046274Written as AcasunlimabReport a problem
Codes
What other systems call acasunlimab · ClinicalTrials.gg INT016743
- UNII (FDA) H52ITZ9X9DACASUNLIMABOne source FDA
- NCI Thesaurus C172194AcasunlimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | H52ITZ9X9D | ACASUNLIMAB | One source FDA |
| NCI Thesaurus | C172194 | Acasunlimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.